The use of orlistat in diabetes: An educational article and expert opinion
Main Article Content
Abstract
In 1998, Hermann Toplak and Marhardt reported the emergence and registration of orlistat in Austria. Orlistat is an intestinal lipase inhibitor which decreases intestinal triglycerides absorption and helps in lowering the ultimate calorie intake. The aim of this paper is to provide an overview of orlistat research progress in diabetes. There has been accumulating convincing evidence suggesting that the use of orlistat in type 2 diabetes can have beneficial effects on diabetic control, body weight, glycosylated hemoglobin (HbA1C), and insulin resistance.
Downloads
Article Details
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.